Randomized Comparative Study of Erlotinib and Pemetrexed in the Maintenance Treatment of Advanced Lung Cancer Patients.

NCT ID: NCT03460678

Last Updated: 2020-03-05

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE4
• Total Enrollment: 9 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-02-28
• Study Completion Date: 2018-11-14

Brief Summary

The purpose of this multicenter randomized study is to compare the effectiveness and safety of erlotinib and pemetrexed in the maintenance treatment of patients with advanced non-squamous non-small cell lung cancer (NSCLC)

Detailed Description

A randomized multi-center prospective study to compare the 12-month effectiveness (survival) and safety of erlotinib and pemetrexed as maintenance treatment in two groups of patients with locally advanced or metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) other than predominantly squamous cell histology, whose disease has not progressed immediately following platinum-based chemotherapy for 4 cycles administered per routine daily practice in each study center

Conditions

Carcinoma, Non-Small-Cell Lung

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Pemetrexed Arm

Vials containing powder for concentrate for solution for infusion equivalent to 500 mg of pemetrexed (as disodium)

Group Type: OTHER

Pemetrexed

Intervention Type: DRUG

Vials containing powder for concentrate for solution for infusion equivalent to 500 mg of pemetrexed (as disodium) administered as 500mg/m2 IV over 10 minutes on the first day of each 21-day cycle, until disease progression or unacceptable toxic effects

Erlotinib Arm

Film coated tablets containing 150 mg erlotinib (as erlotinib hydrochloride)

Group Type: OTHER

Erlotinib

Intervention Type: DRUG

Film coated tablets containing 150 mg erlotinib (as erlotinib hydrochloride) administered once daily until disease progression or unacceptable toxic effects

Interventions

Pemetrexed

Vials containing powder for concentrate for solution for infusion equivalent to 500 mg of pemetrexed (as disodium) administered as 500mg/m2 IV over 10 minutes on the first day of each 21-day cycle, until disease progression or unacceptable toxic effects

Intervention Type: DRUG

Erlotinib

Film coated tablets containing 150 mg erlotinib (as erlotinib hydrochloride) administered once daily until disease progression or unacceptable toxic effects

Intervention Type: DRUG

Other Intervention Names

Pemitra®; Mirata®

Eligibility Criteria

Inclusion Criteria

• Age ≥18 years
• Signed written informed consent
• Histologically or cytological diagnosed stage IIIB/IV non-squamous histology NSCLC
• Received platinum based doublet chemotherapy for 4 cycles as first line therapy before this study
• Patients upon enrolment has at least stable disease following the platinum doublet; with documented (confirmed or unconfirmed) radiographic evidence of a tumor response of complete response (CR), partial response (PR), or stable disease (SD) according to RECIST version 1.1 criteria
• Estimated Life expectancy ≥ 3 months
• Eastern cooperative oncology group performance status (ECOG PS) 0-2
• Adequate organ function

Exclusion Criteria

• Age ˂18 years
• Predominantly squamous cell and/or mixed small cell, non-small cell histology
• Current treatment on another therapeutic clinical study or within the last 30 days of entering the study
• Spinal cord compression unless treated with the patient attaining good pain control and stable or recovered neurologic function, carcinomatous meningitis, or leptomeningeal disease
• Any of the following within the 3 months prior to starting study treatment: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, congestive heart failure, or cerebrovascular accident including transient ischemic attack
• Ongoing cardiac dysrhythmias of national cancer institute-common terminology criteria for adverse events (NCI CTCAE) Grade >2, uncontrolled atrial fibrillation of any grade, or corrected QT interval (QTc) >470 msec
• Pregnancy or breastfeeding
• Prior malignancy (other than current NSCLC): patients will not be eligible if they have evidence of active malignancy (other than non-melanoma skin cancer or localized cervical cancer, or localized and presumed cured prostate cancer) within the last 3 years
• Other severe acute or chronic medical or psychiatric conditions, or laboratory abnormalities that would impose, in the judgment of the investigator and/or sponsor, excessive risk associated with study participation or study drug administration, and which would, therefore, make the patient inappropriate to enter this study
• Uncontrolled third-space fluid collections
• Progressive brain metastases
• Hypersensitivity to the study drugs
• Inability to take corticosteroid drugs, folic acid, or vitamin B12
• Patients with epidermal growth factor receptor (EGFR) positive, anaplastic lymphoma kinase (ALK) positive (documented using fluorescence in situ hybridization (FISH) and/or immunohistochemistry (IHC)), or unknown EGFR and ALK test results

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Hikma Pharmaceuticals LLC

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

King Hussein Cancer Center (KHCC)

Amman, , Jordan

American University of Beirut Medical Center

Beirut, , Lebanon

Countries

Jordan; Lebanon

Other Identifiers

MRT-JOR-LEB-KSA-2016-04

Identifier Type: -

Identifier Source: org_study_id